Cardiovascular Drugs and Therapy

, Volume 26, Issue 4, pp 301–309 | Cite as

Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay

  • P. Ferroni
  • D. Della-Morte
  • A. Pileggi
  • M. G. Valente
  • F. Martini
  • F. La Farina
  • R. Palmirotta
  • L. F. Meneghini
  • T. Rundek
  • C. Ricordi
  • F. Guadagni
Article

Abstract

Purpose

Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay.

Methods

Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls.

Results

Procoagulant status of T2D patients was enhanced when compared to control subjects (p < 0.0001). Similarly, sCD40L levels were increased in T2D (p < 0.0001). When testing ThP as the dependent variable in a multivariate regression model, sCD40L (p < 0.0001) and statin treatment (p = 0.019) were independent predictors of the procoagulant state of T2D patients. Subgroup analysis showed a significant improvement of coagulability in T2D patients on statins (p = 0.012).

Conclusions

The use of a standardized, easy-to-run, and commercially available APC-dependent thrombin-generation assay detected the presence of a procoagulant status in a large series of patients with long-standing T2D and demonstrated a significant impact of statins in the coagulation status of patients with T2D.

Key words

Haemostasis Type 2 Diabetes Dyslipidemia Lipid-Lowering Drugs 

References

  1. 1.
    Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:S19–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis. 2011;31:165–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med. 2006;18:969–74.PubMedGoogle Scholar
  7. 7.
    Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs. 2007;67:17–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Ludwig S, Shen GX. Statins for diabetic cardiovascular complications. Curr Vasc Pharmacol. 2006;4:245–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Guadagni F, Albertini G, Barbanti P, Volterrani M, Palma E, Lancia A, et al. Foundation and Organization of a high-throughput technology-based Multidisciplinary and InterInstitutional Biobank at the IRCCS San Raffaele Pisana. Biopreserv Biobanking. 2010;7:201–2.Google Scholar
  10. 10.
    Guadagni F, Spila A, Nanni U, Somma P, Perrone V, De Angelis F, et al. Automated processing of biological samples. The experience of the InterInstitutional Multidisciplinary Biobank (BioBIM). Biopreserv Biobanking. 2010;7:230–1.Google Scholar
  11. 11.
    Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008;102:1654–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143–421.Google Scholar
  14. 14.
    Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem. 2010;43:666–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res. 2009;124:137–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci. 2006;1084:1–29.PubMedCrossRefGoogle Scholar
  17. 17.
    Ferroni P, La Farina F, Palmirotta R, Martini F, Raparelli V, Nigro C, et al. Predictive value of thrombopath determination in women with pregnancy complications. Clin Chim Acta. 2010;411:37–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, Chantarangkul V, et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis. 2010;30:215–9.PubMedCrossRefGoogle Scholar
  19. 19.
    De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531–44.PubMedGoogle Scholar
  20. 20.
    Krentz A. Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents? Br J Diabetes Vasc Dis. 2002;2:370–8.CrossRefGoogle Scholar
  21. 21.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837–53.Google Scholar
  22. 22.
    Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRefGoogle Scholar
  23. 23.
    Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med. 2002;19:201–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Vasudevan MM, Ballantyne CM. Advances in lipid testing and management in patients with diabetes mellitus. Endocr Pract. 2009;15:641–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Ceriello A, Quatraro A, Marchi E, Barbanti M, Dello Russo P, Lefebvre P, et al. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabet Med. 1990;7:343–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Sauls DL, Banini AE, Boyd LC, Hoffman M. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. J Thromb Haemost. 2007;5:638–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:391–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schönbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res. 2005;2:81–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Neubauer H, Setiadi P, Günesdogan B, Pinto A, Börgel J, Mügge A. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in Type 2 diabetes. Diabet Med. 2010;27:384–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Bláha V, Andrýs C, Smahelová A, Knízek J, Hyspler R, Solichová D, et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res. 2006;54:421–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation. 2003;107:2664–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Santini E, Madec S, Corretti V, Ferrannini E, Solini A. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J Endocrinol Invest. 2008;31:660–5.PubMedGoogle Scholar
  36. 36.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Jaumdally RJ, Lip GY, Varma C, Blann AD. Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes. Angiology. 2011;62:571–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Kannel WB. Overview of atherosclerosis. Clin Ther. 1998;20:B2–B17.PubMedCrossRefGoogle Scholar
  39. 39.
    Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287–94.PubMedCrossRefGoogle Scholar
  40. 40.
    Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol. 2010;21:298–304.PubMedCrossRefGoogle Scholar
  41. 41.
    Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Avogaro A, Guida P, Giorda C, Mannucci E, Medea G, Comaschi M, et al. The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Metab Cardiovasc Dis. 2007;17:32–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena? Vasc Health. Risk Manag. 2010;6:665–9.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • P. Ferroni
    • 1
  • D. Della-Morte
    • 1
    • 2
    • 3
    • 4
  • A. Pileggi
    • 5
    • 6
    • 7
  • M. G. Valente
    • 2
  • F. Martini
    • 1
  • F. La Farina
    • 1
  • R. Palmirotta
    • 1
  • L. F. Meneghini
    • 5
  • T. Rundek
    • 4
  • C. Ricordi
    • 5
    • 6
    • 7
    • 8
  • F. Guadagni
    • 1
    • 2
    • 3
  1. 1.Department of Laboratory Medicine and Advanced BiotechnologiesIRCCS San Raffaele PisanaRomeItaly
  2. 2.InterInstitutional Multidisciplinary Biobank (BioBIM)IRCCS San RaffaeleRomeItaly
  3. 3.Diabetes Research InstituteRomeItaly
  4. 4.Department of Neurology, Miller School of MedicineUniversity of MiamiMiamiUSA
  5. 5.Diabetes Research InstituteUniversity of MiamiMiamiUSA
  6. 6.DeWitt-Daughtry Department of Surgery, Miller School of MedicineUniversity of MiamiMiamiUSA
  7. 7.Department of Microbiology and Immunology, Miller School of MedicineUniversity of MiamiMiamiUSA
  8. 8.Department of Medicine, Miller School of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations